Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
34.62
-0.19 (-0.55%)
Oct 24, 2024, 4:00 PM EDT - Market closed
Edgewise Therapeutics Employees
Edgewise Therapeutics had 88 employees as of December 31, 2023. The number of employees increased by 29 or 49.15% compared to the previous year.
Employees
88
Change (1Y)
29
Growth (1Y)
49.15%
Revenue / Employee
n/a
Profits / Employee
-$1,316,795
Market Cap
3.25B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 88 | 29 | 49.15% |
Dec 31, 2022 | 59 | 28 | 90.32% |
Dec 31, 2021 | 31 | 12 | 63.16% |
Dec 31, 2020 | 19 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Amedisys | 19,000 |
Envista Holdings | 12,800 |
PTC Therapeutics | 1,055 |
Apellis Pharmaceuticals | 706 |
Amicus Therapeutics | 517 |
TG Therapeutics | 264 |
Xenon Pharmaceuticals | 259 |
Kymera Therapeutics | 187 |
EWTX News
- 23 days ago - Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society - Business Wire
- 24 days ago - Analysts Think There's Still Time To Get In On Edgewise - Benzinga
- 4 weeks ago - Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge - Benzinga
- 5 weeks ago - Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment - Benzinga
- 5 weeks ago - Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) - Business Wire
- 5 weeks ago - Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time - Business Wire
- 2 months ago - Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Business Wire
- 2 months ago - Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal - Seeking Alpha